Recombinant vectors comprising genes for binding domains and secretable peptides
WO2017079695A1
Gene expression patterns to predict responsiveness to virotherapy in cancer indications
KR20180048743A
2A < / RTI > peptide.
US2016222412A1
Recombinant vector with stabilizing a-loop
CA2943640A1
A retroviral vector having immune-stimulating activity
WO2015021077A1
Recombinant vector with optimized a-bulge
US2016175388A1
Immunosuppressive components associated with retroviral replicating vectors
US2014178340A1
Cancer combination therapy and recombinant vectors
WO2014066700A1
Retroviral vector with mini-promoter cassette
AU2013205006A1
Gene Therapy Vectors and Cytosine Deaminases
AU2013205004A1
Formulations of 5-fluorocytosine and Uses Thereof
EP2632491A2
Enhanced cancer treatment and monitoring using recombinant vectors
EP2633321A2
Antisera assays for mlv related viruses in humans and other mammals
CN103140581A
Retrovirus detection
EP2547353A2
Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase.